vs
Side-by-side financial comparison of Aligos Therapeutics, Inc. (ALGS) and HALOZYME THERAPEUTICS, INC. (HALO). Click either name above to swap in a different company.
HALOZYME THERAPEUTICS, INC. is the larger business by last-quarter revenue ($451.8M vs $169.0K, roughly 2673.2× Aligos Therapeutics, Inc.). HALOZYME THERAPEUTICS, INC. runs the higher net margin — -31.3% vs -11763.9%, a 11732.6% gap on every dollar of revenue. On growth, HALOZYME THERAPEUTICS, INC. posted the faster year-over-year revenue change (51.6% vs -72.1%). Over the past eight quarters, HALOZYME THERAPEUTICS, INC.'s revenue compounded faster (51.9% CAGR vs -50.7%).
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
ALGS vs HALO — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $169.0K | $451.8M |
| Net Profit | $-19.9M | $-141.6M |
| Gross Margin | — | 82.6% |
| Operating Margin | -12907.7% | -20.6% |
| Net Margin | -11763.9% | -31.3% |
| Revenue YoY | -72.1% | 51.6% |
| Net Profit YoY | 75.8% | -203.3% |
| EPS (diluted) | $4.23 | $-1.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $169.0K | $451.8M | ||
| Q3 25 | $741.0K | $354.3M | ||
| Q2 25 | $965.0K | $325.7M | ||
| Q1 25 | $311.0K | $264.9M | ||
| Q4 24 | $606.0K | $298.0M | ||
| Q3 24 | $1.3M | $290.1M | ||
| Q2 24 | $1.1M | $231.4M | ||
| Q1 24 | $694.0K | $195.9M |
| Q4 25 | $-19.9M | $-141.6M | ||
| Q3 25 | $-31.5M | $175.2M | ||
| Q2 25 | $-15.9M | $165.2M | ||
| Q1 25 | $43.1M | $118.1M | ||
| Q4 24 | $-82.2M | $137.0M | ||
| Q3 24 | $-19.3M | $137.0M | ||
| Q2 24 | $5.1M | $93.2M | ||
| Q1 24 | $-34.9M | $76.8M |
| Q4 25 | — | 82.6% | ||
| Q3 25 | — | 84.4% | ||
| Q2 25 | — | 85.8% | ||
| Q1 25 | — | 81.7% | ||
| Q4 24 | — | 85.9% | ||
| Q3 24 | — | 83.0% | ||
| Q2 24 | — | 82.9% | ||
| Q1 24 | — | 85.5% |
| Q4 25 | -12907.7% | -20.6% | ||
| Q3 25 | -3827.4% | 61.5% | ||
| Q2 25 | -1924.0% | 62.2% | ||
| Q1 25 | -6187.5% | 53.4% | ||
| Q4 24 | -3393.2% | 58.9% | ||
| Q3 24 | -1610.5% | 56.3% | ||
| Q2 24 | -2489.5% | 50.7% | ||
| Q1 24 | -3176.7% | 48.8% |
| Q4 25 | -11763.9% | -31.3% | ||
| Q3 25 | -4256.0% | 49.5% | ||
| Q2 25 | -1643.8% | 50.7% | ||
| Q1 25 | 13854.7% | 44.6% | ||
| Q4 24 | -13556.1% | 46.0% | ||
| Q3 24 | -1540.7% | 47.2% | ||
| Q2 24 | 477.0% | 40.3% | ||
| Q1 24 | -5023.5% | 39.2% |
| Q4 25 | $4.23 | $-1.13 | ||
| Q3 25 | $-3.04 | $1.43 | ||
| Q2 25 | $-1.53 | $1.33 | ||
| Q1 25 | $-2.11 | $0.93 | ||
| Q4 24 | $-13.10 | $1.06 | ||
| Q3 24 | $-3.07 | $1.05 | ||
| Q2 24 | $0.81 | $0.72 | ||
| Q1 24 | $-5.58 | $0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.8M | $133.8M |
| Total DebtLower is stronger | — | $2.1B |
| Stockholders' EquityBook value | $53.5M | $48.8M |
| Total Assets | $88.5M | $2.5B |
| Debt / EquityLower = less leverage | — | 43.89× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $77.8M | $133.8M | ||
| Q3 25 | $99.1M | $419.7M | ||
| Q2 25 | $122.9M | $61.9M | ||
| Q1 25 | $137.9M | $176.3M | ||
| Q4 24 | $56.9M | $115.8M | ||
| Q3 24 | $74.9M | $154.3M | ||
| Q2 24 | $94.5M | $187.9M | ||
| Q1 24 | $112.7M | $164.6M |
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | — | $1.5B |
| Q4 25 | $53.5M | $48.8M | ||
| Q3 25 | $71.8M | $503.9M | ||
| Q2 25 | $101.9M | $332.7M | ||
| Q1 25 | $116.4M | $482.3M | ||
| Q4 24 | $-29.0M | $363.8M | ||
| Q3 24 | $50.1M | $452.7M | ||
| Q2 24 | $67.2M | $289.4M | ||
| Q1 24 | $59.8M | $177.8M |
| Q4 25 | $88.5M | $2.5B | ||
| Q3 25 | $109.8M | $2.2B | ||
| Q2 25 | $134.7M | $2.1B | ||
| Q1 25 | $150.7M | $2.2B | ||
| Q4 24 | $70.1M | $2.1B | ||
| Q3 24 | $88.4M | $2.1B | ||
| Q2 24 | $108.8M | $2.0B | ||
| Q1 24 | $127.9M | $1.8B |
| Q4 25 | — | 43.89× | ||
| Q3 25 | — | 3.00× | ||
| Q2 25 | — | 4.54× | ||
| Q1 25 | — | 3.13× | ||
| Q4 24 | — | 4.14× | ||
| Q3 24 | — | 3.32× | ||
| Q2 24 | — | 5.19× | ||
| Q1 24 | — | 8.44× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-21.7M | $219.0M |
| Free Cash FlowOCF − Capex | — | $217.6M |
| FCF MarginFCF / Revenue | — | 48.2% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $644.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-21.7M | $219.0M | ||
| Q3 25 | $-24.3M | $178.6M | ||
| Q2 25 | $-15.5M | $99.7M | ||
| Q1 25 | $-20.9M | $154.2M | ||
| Q4 24 | $-18.4M | $178.5M | ||
| Q3 24 | $-20.1M | $115.4M | ||
| Q2 24 | $-19.5M | $55.8M | ||
| Q1 24 | $-22.7M | $129.4M |
| Q4 25 | — | $217.6M | ||
| Q3 25 | — | $175.6M | ||
| Q2 25 | — | $98.1M | ||
| Q1 25 | — | $153.3M | ||
| Q4 24 | — | $175.4M | ||
| Q3 24 | — | $113.9M | ||
| Q2 24 | — | $53.2M | ||
| Q1 24 | — | $125.9M |
| Q4 25 | — | 48.2% | ||
| Q3 25 | — | 49.6% | ||
| Q2 25 | — | 30.1% | ||
| Q1 25 | — | 57.9% | ||
| Q4 24 | — | 58.9% | ||
| Q3 24 | — | 39.3% | ||
| Q2 24 | — | 23.0% | ||
| Q1 24 | — | 64.3% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 1.0% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 1.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.02× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | -0.49× | 1.31× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | -3.85× | 0.60× | ||
| Q1 24 | — | 1.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALGS
Segment breakdown not available.
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
